2,3,4,5,6-pentafluoro-N-methylbenzamide | 120033-88-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4,5,6-pentafluoro-N-methylbenzamide
• 英文别名: N-methylpentafluorobenzamide；Benzamide, pentafluoro-N-methyl-
• CAS: 120033-88-7
• 化学式: C₈H₄F₅NO
• 分子量: 225.118
• InChiKey: AQQNFZYJRSIRRV-UHFFFAOYSA-N

物化性质

• 熔点：
  98-99 °C(Solv: toluene (108-88-3))
• 沸点：
  122.5±40.0 °C(Predicted)
• 密度：
  1.492±0.06 g/cm3(Predicted)
• 保留指数：
  1302

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(三氟甲硫基)邻苯二甲酰亚胺 、 2,3,4,5,6-pentafluoro-N-methylbenzamide 在 2,4,5,6-四(9H-咔唑-9-基)异酞腈 作用下， 以 乙腈 为溶剂， 以74 %的产率得到
  参考文献：
  名称：

  N-酰基胺的光催化 α-三氟甲硫基化

  摘要：

  报道了一种在温和反应条件下对酰胺进行 C(sp 3 )–H 三氟甲硫基化的光催化方法。我们开发了一种方案，可以耐受多种官能团，并通过使用低催化负载的有机光催化剂，以高产率（26 个例子，高达 83% 的产率）对芳香族和脂肪族酰胺进行官能化。通过该方法，成功合成了原始氟化无环硫胺醛。进行了详细的机理研究，并能够通过质子耦合电子转移（PCET）破译氧化猝灭催化循环，从而在氮的 α 位形成初级自由基。

  DOI：

  10.1021/acscatal.3c03249
• 作为产物：
  描述：

  五氟苯甲酰氯 、 盐酸甲胺 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 以47%的产率得到2,3,4,5,6-pentafluoro-N-methylbenzamide
  参考文献：
  名称：

  Electrochemical models for cytochrome P-450. N-Demethylation of tertiary amides by anodic oxidation

  摘要：

  DOI：

  10.1021/jo00271a040

文献信息

• Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof
  申请人：REICH Melanie

  公开号：US20090069320A1

  公开（公告）日：2009-03-12

  Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.

  根据公式I的4-氨基喹唑啉化合物替代物，其生产方法，含有这些化合物的药物组合物以及用于治疗或抑制疾病状态或疾病状态的用途。
• Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  申请人：Cid-Nunez Jose Maria

  公开号：US20080262076A1

  公开（公告）日：2008-10-23

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D 2 receptors, towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃衍生物，其含有一个环状胺侧链，具有结合多巴胺受体的亲和力，特别是多巴胺D2受体，对5-HT2A和5-HT2C受体的亲和力，以及包含根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力紊乱，并提供其生产过程。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐、N-氧化物形式或季铵盐，其中所有取代基在权利要求书1中定义。
• Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
  申请人：UNIVERSITA' DEGLI STUDI DIPALERMO

  公开号：US11203578B2

  公开（公告）日：2021-12-21

  Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.

  公开了噁二唑衍生物、其作为药物的用途，特别是用于治疗与基因中存在无义突变或 mRNA 中存在过早终止密码子有关的疾病、包含所述噁二唑衍生物和原药或其混合物的药物制剂以及制备所述噁二唑衍生物的方法。
• Compounds for Increasing Lipid Synthesis and Storage
  申请人：NUtech Ventures

  公开号：US20160312253A1

  公开（公告）日：2016-10-27

  This invention relates to methods for increasing lipid accumulation and lipid production in cells. Methods of producing biofuel from cells and preparing nutraceuticals comprising lipids produced according to a method provided herein are also provided.
• OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES DUE TO NONSENSE MUTATIONS
  申请人：UNIVERSITA' DEGLI STUDI DIPALERMO

  公开号：US20210002238A1

  公开（公告）日：2021-01-07

  Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.